Histidine-tryptophan-ketoglutarate solution for donor heart preservation is safe for transplantation.
Various solutions are used for donor heart preservation. We examine outcomes in our heart transplant population where histidine-tryptophan-ketoglutarate (HTK) solution have been used for heart preservation since 2004. Retrospective review of the United Network for Organ Sharing database (UNOS, 2004-2016) comparing our heart transplant outcomes with other national centers. Propensity matching in a 1:3 ratio was performed to adjust for preoperative recipient variables. Following propensity matching, comparing UNOS outcomes (n=1080) with our institutional data (n=360), there was no difference in matched preoperative parameters. Donor hearts were similar for donor age, gender, donor-recipient size ratio, LVEF, and ischemic time. The Michigan HTK cohort had a larger proportion with donor cardiac arrest (26.3% vs 6.1%, P<0.001), and longer cardiac arrest duration (22.1+16.0 vs 17.2+14.0 mins, P=0.052). Our primary graft dysfunction (PGD) rate requiring mechanical support was (n=15, 4.2%). Postoperative mechanical support utilized for PGD included extracorporeal membrane oxygenation (n=9, 60.0%), intra-aortic balloon pump (n=4, 26.7%), RVAD (n=3, 20%), and biventricular assist device (n=3, 20%). Overall survival at our institution was similar to the national average (P=0.649). Survival at 1, 5 and 10 years with HTK was 92.2%, 81.3%, and 70.8%, and for the UNOS population was 91.6%, 80.3%, and 62.0%. Use of HTK solution for donor hearts was associated with a low rate of severe PGD. Overall survival was not significantly different to other institutions using a variety of preservation solutions in the UNOS database during the same period. HTK solution is efficacious for preservation of donor hearts.